Get the Stockscreener App
4.86
6.72%
-0.35
Dbv Technologies Adr stock is traded at $4.86, with a volume of 12,895.
It is down -6.72% in the last 24 hours and up +10.58% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
See More
Previous Close:
$5.21
Open:
$4.84
24h Volume:
12,895
Relative Volume:
0.08
Market Cap:
$100.96M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-4.6286
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+16.39%
1M Performance:
+10.58%
6M Performance:
+33.94%
1Y Performance:
-40.21%
1-Day Range:
$4.75
$4.9209
1-Week Range:
$4.15
$5.30
52-Week Range:
$2.2045
$8.318
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
4.75 | 100.96M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
507.23 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.00 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
597.25 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.07 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.88 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials By Investing.com - Investing.com South Africa
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials - Investing.com India
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
JMP reiterates DBV Technologies stock with $10 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
DBV Technologies (DBVT) to Release Earnings on Thursday - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - TradingView
Can This Peanut Patch Help Children Safely Eat 3-4 Peanuts? New 5-Year Data Reveals Promising Results - StockTitan
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com India
DBV Technologies' SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) vs. Allogene Therapeutics (NASDAQ:ALLO) Critical Contrast - Defense World
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com - MarketBeat
DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - TradingView
DBV Technologies stock holds firm with $10 target from JMP By Investing.com - Investing.com South Africa
DBV Technologies stock holds firm with $10 target from JMP - Investing.com India
DBV Technologies (NASDAQ:DBVT) Shares Cross Above Fifty Day Moving Average – Time to Sell? - Defense World
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT) - Defense World
Patch effective through 36 months in treating toddlers with peanut allergy - Healio
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - MSN
DBV Technologies Reports H2 2024 Liquidity Contract Results: 440,957 Shares Traded - StockTitan
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
| Mohideen Pharis | Chief Medical Officer |
May 24 '24 |
Sale |
1.36 |
660 |
898 |
81,152 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '24 |
Sale |
1.38 |
382 |
527 |
81,812 |
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):